Roche and Amira collaborate against inflammatory diseases

Under the research collaboration, Roche will use its screening capabilities to investigate three mutually agreed targets in the field of inflammatory diseases. Amira will then utilize its expertise to optimize the lead compounds generated. Roche will have opt-in rights on two of those compounds.

Under a separate licensing option agreement, Amira may license two pre-determined clinical programs from Roche in specific indications in exchange for equity, milestones and royalties.

The alliance with Amira complements Roche’s broad research efforts in inflammation and provides the company with access to innovative external capabilities in a strategic therapeutic area.

“We are very excited to collaborate with Roche. This alliance reinforces the proven pharmaceutical background of Amira’s scientists and positions Amira to develop an outstanding pipeline of novel drug candidates for a broad array of inflammation-based disorders,” said Peppi Prasit, chief scientific officer of Amira.